These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37942138)

  • 61. White matter hyperintensities are not associated with cognitive decline in early Parkinson's disease - The DeNoPa cohort.
    Hanning U; Teuber A; Lang E; Trenkwalder C; Mollenhauer B; Minnerup H
    Parkinsonism Relat Disord; 2019 Dec; 69():61-67. PubMed ID: 31678722
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Speech difficulties in early de novo patients with Parkinson's disease.
    Polychronis S; Niccolini F; Pagano G; Yousaf T; Politis M
    Parkinsonism Relat Disord; 2019 Jul; 64():256-261. PubMed ID: 31078401
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.
    Nombela C; Rowe JB; Winder-Rhodes SE; Hampshire A; Owen AM; Breen DP; Duncan GW; Khoo TK; Yarnall AJ; Firbank MJ; Chinnery PF; Robbins TW; O'Brien JT; Brooks DJ; Burn DJ; ; Barker RA
    Brain; 2014 Oct; 137(Pt 10):2743-58. PubMed ID: 25080285
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CSF Aβ
    Ba M; Yu G; Kong M; Liang H; Yu L
    Transl Neurodegener; 2018; 7():22. PubMed ID: 30338062
    [TBL] [Abstract][Full Text] [Related]  

  • 65. White Matter Hyperintensities Mediate Impact of Dysautonomia on Cognition in Parkinson's Disease.
    Dadar M; Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB; Collins DL
    Mov Disord Clin Pract; 2020 Aug; 7(6):639-647. PubMed ID: 32775509
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Age-Related Association Between APOE ɛ4 and Cognitive Progression in de novo Parkinson's Disease.
    Liu JY; Ma LZ; Wang J; Cui XJ; Sheng ZH; Fu Y; Li M; Ou YN; Yu JT; Tan L; Lian Y
    J Alzheimers Dis; 2023; 91(3):1121-1132. PubMed ID: 36565124
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Poor attentional function predicts cognitive decline in patients with non-demented Parkinson's disease independent of motor phenotype.
    Taylor JP; Rowan EN; Lett D; O'Brien JT; McKeith IG; Burn DJ
    J Neurol Neurosurg Psychiatry; 2008 Dec; 79(12):1318-23. PubMed ID: 18586866
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition.
    Wojtala J; Heber IA; Neuser P; Heller J; Kalbe E; Rehberg SP; Storch A; Linse K; Schneider C; Gräber S; Berg D; Dams J; Balzer-Geldsetzer M; Hilker-Roggendorf R; Oberschmidt C; Baudrexel S; Witt K; Schmidt N; Deuschl G; Mollenhauer B; Trenkwalder C; Liepelt-Scarfone I; Spottke A; Roeske S; Wüllner U; Wittchen HU; Riedel O; Dodel R; Schulz JB; Reetz K
    J Neurol Neurosurg Psychiatry; 2019 Feb; 90(2):171-179. PubMed ID: 30297519
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Beta amyloid deposition and cognitive decline in Parkinson's disease: a study of the PPMI cohort.
    Mihaescu AS; Valli M; Uribe C; Diez-Cirarda M; Masellis M; Graff-Guerrero A; Strafella AP
    Mol Brain; 2022 Sep; 15(1):79. PubMed ID: 36100909
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Olfactory anosognosia is a predictor of cognitive decline and dementia conversion in Parkinson's disease.
    Yoo HS; Chung SJ; Lee YH; Ye BS; Sohn YH; Lee PH
    J Neurol; 2019 Jul; 266(7):1601-1610. PubMed ID: 31011798
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Computerized testing in Parkinson's disease: Performance deficits in relation to standard clinical measures.
    Flannery SL; Jowett T; Garvey A; Cutfield NJ; Machado L
    J Clin Exp Neuropsychol; 2018 Dec; 40(10):1062-1073. PubMed ID: 29978753
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2).
    Yousaf T; Pagano G; Niccolini F; Politis M
    J Neurol; 2019 May; 266(5):1203-1210. PubMed ID: 30820739
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gastrointestinal symptoms are predictive of trajectories of cognitive functioning in de novo Parkinson's disease.
    Jones JD; Rahmani E; Garcia E; Jacobs JP
    Parkinsonism Relat Disord; 2020 Mar; 72():7-12. PubMed ID: 32058266
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical Characterization of Parkinson's Disease Patients With Cognitive Impairment.
    Simon-Gozalbo A; Rodriguez-Blazquez C; Forjaz MJ; Martinez-Martin P
    Front Neurol; 2020; 11():731. PubMed ID: 32849203
    [No Abstract]   [Full Text] [Related]  

  • 75. Pro-Saccades Predict Cognitive Decline in Parkinson's Disease: ICICLE-PD.
    Stuart S; Lawson RA; Yarnall AJ; Nell J; Alcock L; Duncan GW; Khoo TK; Barker RA; Rochester L; Burn DJ;
    Mov Disord; 2019 Nov; 34(11):1690-1698. PubMed ID: 31442355
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson's Disease.
    Michels J; van der Wurp H; Kalbe E; Rehberg S; Storch A; Linse K; Schneider C; Gräber S; Berg D; Dams J; Balzer-Geldsetzer M; Hilker-Roggendorf R; Oberschmidt C; Baudrexel S; Witt K; Schmidt N; Deuschl G; Mollenhauer B; Trenkwalder C; Liepelt-Scarfone I; Spottke A; Roeske S; Wüllner U; Wittchen HU; Riedel O; Kassubek J; Dodel R; Schulz JB; Costa AS; Reetz K
    J Parkinsons Dis; 2022; 12(3):905-916. PubMed ID: 35068416
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Assessment of a prognostic MRI biomarker in early de novo Parkinson's disease.
    Zeighami Y; Fereshtehnejad SM; Dadar M; Collins DL; Postuma RB; Dagher A
    Neuroimage Clin; 2019; 24():101986. PubMed ID: 31514113
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Frontostriatal and limbic contributions to cognitive decline in Parkinson's disease.
    Brown G; Hakun J; Lewis MM; De Jesus S; Du G; Eslinger PJ; Kong L; Huang X
    J Neuroimaging; 2023 Jan; 33(1):121-133. PubMed ID: 36068704
    [TBL] [Abstract][Full Text] [Related]  

  • 79. White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients.
    Dadar M; Zeighami Y; Yau Y; Fereshtehnejad SM; Maranzano J; Postuma RB; Dagher A; Collins DL
    Neuroimage Clin; 2018; 20():892-900. PubMed ID: 30292088
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changes.
    Jones JD; Uribe C; Bunch J; Thomas KR
    J Neurol; 2021 Jan; 268(1):337-345. PubMed ID: 32804281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.